PI
ASBPW

PEAK6 Investments’s Aspire Biopharma Warrant ASBPW Stock Holding History

PEAK6 Investments’s Portfolio ASBPW Stock Details ASBPW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		$529 Hold
12,500
– – ﹤0.01% 3389
2024
Q2 		$375 Hold
12,500
– – ﹤0.01% 3463
2024
Q1 		$376 Hold
12,500
– – ﹤0.01% 3916
2023
Q4 		$750 Hold
12,500
– – ﹤0.01% 4078
2023
Q3 		$634 Hold
12,500
– – ﹤0.01% 3956
2023
Q2 		$626 Hold
12,500
– – ﹤0.01% 3806
2023
Q1 		$523 Hold
12,500
– – ﹤0.01% 4148
2022
Q4 		$999 Hold
12,500
– – ﹤0.01% 4233
2022
Q3 		$1K Sell
12,500
-12,500
-50% -$1.82K ﹤0.01% 4807
2022
Q2 		$2.63K Buy
+25,000
New +$5.44K ﹤0.01% 5957

Other funds holding ASBPW

AC
Athos Capital Hong Kong $324M AUM 16.62% 1-Year Est. Return
HCM
Highbridge Capital Management New York $3.09B AUM 31.19% 1-Year Est. Return
SCM
Saba Capital Management New York $3.62B AUM 13% 1-Year Est. Return
LA
Linden Advisors New York $17.9B AUM 1.72% 1-Year Est. Return
AA
AQR Arbitrage Greenwich, Connecticut $6.09B AUM 27.01% 1-Year Est. Return
PC
Periscope Capital Toronto, Ontario, Canada $902M AUM 6.51% 1-Year Est. Return
SC
Sculptor Capital New York $9.61B AUM 27.49% 1-Year Est. Return
Verition Fund Management
Verition Fund Management Greenwich, Connecticut $15.4B AUM 30.69% 1-Year Est. Return
WAM
Wolverine Asset Management Chicago, Illinois $10.4B AUM 4.78% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

PEAK6 Investments's ASBPW Position: Q3 2024 in Review

PEAK6 Investments held its Aspire Biopharma Warrant (ASBPW) position steady in Q3 2024 at 12,500 shares worth $529. The position accounts for ﹤0.01% of the portfolio, ranked #3389.

PEAK6 Investments first reported a position in ASBPW in Q2 2022 and has held it in 10 quarters since. The position peaked at $2.63K in Q2 2022. 30 funds tracked by Wall St. Rank hold ASBPW as of Q3 2024.

  • PEAK6 Investments held 12,500 shares of Aspire Biopharma Warrant worth $529 as of Q3 2024.
  • PEAK6 Investments left its Aspire Biopharma Warrant share count unchanged in Q3 2024.
  • Aspire Biopharma Warrant made up ﹤0.01% of PEAK6 Investments's portfolio in Q3 2024, its #3389 holding.
  • PEAK6 Investments first reported a position in Aspire Biopharma Warrant in Q2 2022 and has held it in 10 quarters since.
  • PEAK6 Investments's Aspire Biopharma Warrant position peaked at $2.63K in Q2 2022.
  • 30 funds tracked by Wall St. Rank held Aspire Biopharma Warrant as of Q3 2024.

Based on PEAK6 Investments's 13F filing for Q3 2024, filed 14 Nov 2024.